A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (PORTER)

Leonardo Nissola¹, Karen Autio², Nina Bhardwaj³, Matthew D. Galsky⁴, Kristopher Wentzel⁵, Vanessa M. Hubbard-Lucey⁶, Theresa LaVallee⁷, Cheryl Selinsky⁸, Christopher Perry⁹, Christopher Cabanski¹, Ari J. Bitton¹, Justin Fairchild¹, Christine Horak⁶, Jeffrey Skolnik⁷, Michael Yellin⁸, Ute Dugan⁹, Ramy Ibrahim¹, Lawrence Fong⁹.

¹Parker Institute for Cancer Immunotherapy, ²Memorial Sloan Kettering Cancer Center, ³The Mount Sinai Hospital, ⁴The Angeles Clinic & Research Institute, ⁵Cancer Research Institute, ⁶Bristol-Myers Squibb, ⁷Inovio Pharmaceuticals, ⁸Celldex Therapeutics, ⁹University of California, San Francisco

BACKGROUND

Metastatic castration-resistant prostate cancer (mCRPC), the lethal form of prostate cancer, has shown limited benefit from immune checkpoint inhibition as monotherapy, with two randomized phase 3 trials with ipilimumab failing to show a survival benefit, and a large phase 2 trial with pembrolizumab demonstrating an overall response rate (ORR) of 3-5%. Clearly, a deeper understanding of the biology of prostate cancer, inclusive of the immune microenvironment is needed to inform rational combination strategies in this disease.

PORTER is an open-label, non-randomized, multi-arm, multi-stage, exploratory platform study designed to assess the safety and antitumor activity of multiple immunotherapy combinations in participants with mCRPC who have received and progressed on prior secondary androgen receptor signaling inhibitor therapy.

Coupled with deep immune biomarker profiling, this design will enable rapid insights into the immune responses for each combination, providing premise for future larger validation studies, while also generating hypotheses for new cohorts.

OBJECTIVES, STAGES AND EXPANSION

Primary Endpoint
- Safety, as assessed by the incidence and severity of adverse events.

Secondary Endpoints:
- Composite Objective Response Rate (PSA reduction ≥ 50%, confirmed CR or PR per RECIST v1.1, or change in circulating tumor cell (CTC) from ≥ 5 cells/7.5 mL to ≤ 4 cells/7.5 mL)
- Disease Control Rate
- Radiographic Progression-Free Survival
- Overall Survival

Exploratory endpoints:
- Association of tissue, blood and stool biomarkers with treatment and clinical outcomes.

Stages and Expansion
Each cohort has a two-stage design (initial n = 15, expansion n = 15) with a decision to expand based on the safety, clinical activity, and biomarker results observed in the initial stage.

PATIENT POPULATION

Key Common Inclusion Criteria
- Adenocarcinoma of the prostate
- mCRPC
- Castrate-level testosterone (<50 ng/dL)
- Progressed after abiraterone, enzalutamide and/or apalutamide
- Chemo naive or post chemo if no progression of disease on chemotherapy

Key Common Exclusion Criteria
- Known history of active non-infectious pneumonitis
- Active infection requiring systemic therapy
- Known history of + testing for HIV, Hep B or C
- Known/active CNS metastases

The trial is open & recruiting, for more information on this trial visit: [https://www.parkerici.org/clinical-trial/the-porter-trial/](https://www.parkerici.org/clinical-trial/the-porter-trial/) [https://clinicaltrials.gov/ct2/show/NCT03835533](https://clinicaltrials.gov/ct2/show/NCT03835533)

PLATFORM STUDY SCHEMA

CLINICAL TRIAL STATUS

• First participant enrolled July 2019
• Participating sites:
  - MD Anderson Cancer Center
  - Memorial Sloan Kettering Cancer Center
  - The Mount Sinai Hospital
  - The Angeles Clinic & Research Institute
  - University of California, San Francisco
  - Oregon Health & Science University
• New cohorts using novel immunotherapy combinations are under consideration.

LEGEND
• C = Cycle
• EOT = End of treatment
• N = Sample size
• SC = Subcutaneous
• IM = Intramuscular
• IV = Intravenous
• PR = Partial response
• EP = Electroporation
• PAMP = Pathogen-associated molecular patterns
• QD = Once a day
• b.i.w = Twice a week
• DCs = Dendritic cells
• CR = Complete response

ACKNOWLEDGEMENTS

We extend our gratitude to the patients, their families, and the clinical investigators and their site staff members who are making this trial possible. This study is sponsored by Parker Institute for Cancer Immunotherapy (PICI) and co-funded by the Cancer Research Institute (CRI) and BMS. We appreciate the support of our partners Inovio, Celldex and Oncoerv.

Inovio Pharmaceuticals
Celldex Therapeutics
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY